Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Studies

Trials grouped by drug. Open a study for its arms and the response, survival, and safety figures a source reports.

28 studies across 17 of 17 drugs. 28 studies are in the file.

Atezolizumab + Imatinib1 study

  • ATEZOGISTNCT05152472Phase 2Active, not recruitingn 58

Avapritinib2 studies

  • NAVIGATORNCT02508532Phase 1Completedn 250
  • VOYAGERNCT03465722Phase 3Completedn 476

Belzutifan1 study

Bezuclastinib + Sunitinib1 study

  • PeakNCT05208047Phase 3Recruitingn 482

DCC-30091 study

Envafolimab + Regorafenib1 study

Imatinib5 studies

NB0032 studies

NN3201 (KIT Antibody-drug Conjugate, MMAE)1 study

Olverembatinib (HQP1351)2 studies

Pimitespib + Imatinib1 study

  • NCT05245968NCT05245968Phase 1Active, not recruitingn 78

Regorafenib1 study

  • GRIDNCT01271712Phase 3Completedn 199

Ripretinib3 studies

  • INVICTUSNCT03353753Phase 3Completedn 129
  • INTRIGUENCT03673501Phase 3Active, not recruitingn 453
  • INSIGHTNCT05734105Phase 3Active, not recruitingn 54

Rivoceranib + Paclitaxel1 study

Sunitinib1 study

  • Study 1NCT00075218Phase 3Completedn 361

Velzatinib (IDRX-42, GSK6042981)3 studies

Ziftomenib + Imatinib1 study